Pivotal phase II/III trial of a house dust mite allergy immunotherapy tablet in patients with house dust mite-induced allergic rhinitis

Trial Profile

Pivotal phase II/III trial of a house dust mite allergy immunotherapy tablet in patients with house dust mite-induced allergic rhinitis

Completed
Phase of Trial: Phase II/III

Latest Information Update: 06 Mar 2017

At a glance

  • Drugs House dust mite allergy immunotherapy-ALK Abello (Primary)
  • Indications Allergic rhinitis
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Torii Pharmaceutical
  • Most Recent Events

    • 06 Mar 2017 A Subgroup Analysis of Results from a DBPC Phase III Trial presented at the 2017 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
    • 15 Nov 2016 Results published in the Journal of Allergy and Clinical Immunology
    • 26 Nov 2015 According to an ALK-Torii Pharmaceutical media release, MITICURE will be available for prescription in Japan for adults and adolescents from 12 to 64 years of age and will be launched by the beginning of December-2015.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top